5-HT₇ receptor as a potential therapeutic target in irritable bowel syndrome: Current insights and future perspectives.

Authors

Zuzanna Kasprzak, Maria Jaczynska, Julia Jarzabek, Maciej Salaga

Published in

Drug discovery today. Pages 104811. Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Irritable bowel syndrome (IBS) affects up to 9% of the population worldwide, but current therapies benefit only 25-30% of patients. Disrupted serotonin (5-HT) signaling alters gut microbiota, permeability and immunity, driving IBS pathogenesis. The serotonin type 7 receptor (5-HT₇R), which is widely expressed in both central and peripheral tissues, has emerged as a promising therapeutic target. 5-HT₇R regulates peristalsis, modulates dendritic cell morphology and drives anti-inflammatory responses. Furthermore, 5-HT₇R antagonists induce analgesia and reduce mucosal innervation. This review summarizes the crucial role of 5-HT₇R in the gastrointestinal tract and highlights its potential for future IBS therapy.

PMID:
42785664
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.